How Sarcoma Defies Conventional Oncology Pathways

The complexity surrounding a diagnosis of sarcoma stems from the spectrum of behavior across histologic subtypes. These tumors are rare enough that many oncologists see only a handful over the course of their entire careers. This complexity and limited exposure means physician experience with the disease directly influences outcomes—from anatomic challenges that can determine whether a patient keeps a limb, to a nuanced decision around conventional chemotherapy vs. immunotherapy. Sarcoma care requires the kind of specialized expertise that only develops through high-volume practice dedicated to the treatment of these patients.

The Subtype Challenge

There are more than 70 sarcoma subtypes, and misdiagnosis results in inaccurate treatment decisions. Moffitt’s sarcoma-specific pathologists routinely use immunohistochemistry, molecular profiling, cytogenetics and next-generation sequencing to properly characterize the lesions, identify targetable mutations, and guide treatment. These findings inform the overall treatment plan—including surgical strategy, radiation, and/or systemic therapy—and the sequence of that approach is just as critical as the components. Early referral ensures therapy sequencing aligns with modern practice.  

As a high-volume, NCI-designated Comprehensive Cancer Center, Moffitt’s Sarcoma Program focuses exclusively on bone and soft tissue malignancies.

Why the Biopsy Itself Is a Surgical Decision

Most oncologists think of a biopsy as a diagnostic procedure. In sarcoma, it's the first surgical decision, and the method and approach matter just as much as the result.

Poorly performed biopsies using antiquated techniques can seed tumor cells, increasing the risk of local recurrence or requiring more extensive tissue resection than the tumor itself would have demanded. Excisional biopsies (operations without a diagnosis) can eliminate the chance for limb-sparing surgery or result in highly morbid resections with a complex flap reconstruction. These risks underscore the value of early referral to Moffitt. We plan biopsies collaboratively across specialties, using specific MRI and CT protocols to map tumor extent and guide biopsy placement.

High-Volume Surgical Supporting Improved Outcomes

Achieving negative margins while preserving function is imperative for optimal outcomes. These high-stakes decisions include complex reconstruction approaches, multivisceral resections, and navigated pelvic/sacral surgery, all of which require specialized expertise.

High-volume centers have better patient outcomes. While some hospitals perform these surgeries occasionally, Moffitt surgeons do this work every day. Our sarcoma teams span orthopedic, surgical, vascular, and reconstructive specialties working in concert, supported by computer-assisted navigation and 3D imaging to define precise margins and plan reconstruction. 

Preserving limbs is a top priority, and our surgeons provide the latest in limb salvage reconstructive techniques, including endoprostheses and custom 3-D printed implants. When limb preservation is not possible, we offer osseointegration for amputees. For pediatric patients, we offer expandable endoprostheses that grow with the child, avoiding limb-lengthening surgeries through our collaboration with Johns Hopkins All Children’s.  

Decisions Driven by Biology

Chemotherapy is highly effective for Ewing sarcoma and osteosarcoma but has limited efficacy for most chondrosarcomas and dedifferentiated liposarcomas. Ideal radiation timing also differs among subtypes.

Moffitt’s weekly Sarcoma Tumor Board, comprising dedicated medical oncologists, radiation oncologists, surgeons, pathologists, and radiologists, provides consensus treatment decisions based on up-to-date subtype-specific data and functional goals. This team-based approach to a single, individualized treatment is critical for optimal outcomes.

Treatment options span the full spectrum of standard-of-care therapies, including chemotherapy, radiation, and targeted therapy. We also offer advanced techniques such as IMRT and proton radiation therapy, as well as complex combined-modality approaches. All patients are screened for clinical trial eligibility from our robust portfolio that includes vaccines, cellular therapies and targeted agents for rare cancer types.

Cellular Immunotherapy and Investigational Treatment Options

Immunotherapy options for solid tumors continue to expand. Immune checkpoint therapy, TCR-engineered T cell therapy, and tumor-infiltrating lymphocyte (TIL) therapy have shown promise in select sarcoma subtypes, and we now offer the only FDA-approved cell therapy for sarcoma. Managing these treatments requires infrastructure not available at most community programs.

Moffitt's Immune Cell Therapy (ICE-T) service evolved from a collaboration between hematologic malignancy and solid tumor specialists, including the Sarcoma Program, giving this team deep expertise in recognizing and treating immune-related complications. For patients with high-risk or refractory disease, access to investigational trials may extend survival when standard regimens are no longer effective.

Importance of Clinical Trials

Because sarcomas are rare and evidence-based guidelines are often limited, clinical trial access is essential — and early referral connects your patients to that portfolio before options narrow. Moffitt participated in the trial that produced the first FDA-approved cellular therapy for a sarcoma subtype, and the first of its kind approved for any solid tumor. We are also participating in a trial for another sarcoma subtype that has shown positive results for the first time in more than 20 years.  

Coordinated Care Across the Age Spectrum

Adolescents and young adults often fall between pediatric and adult protocols. Collaboration between Moffitt's AYA care team, the Sarcoma Program, and Johns Hopkins All Children's means families have access to evidence-based guidelines including fertility preservation counseling, psychosocial support, and survivorship planning—and they aren’t choosing between centers or receiving conflicting recommendations.  

Long-Term Surveillance and Supportive Care

Recurrence rates and patterns differ greatly depending on subtype, grade and anatomic site, so generic screening protocols can miss these meaningful signals. When you loop Moffitt in early, our dedicated Sarcoma Program coordinates long-term follow-up tailored to each patient’s case, including subtype-specific imaging strategies, subspecialty rehabilitation, cardiovascular symptom monitoring, and psychosocial support.